Enzo Biochem EBITDA 2010-2023 | ENZ

Enzo Biochem ebitda from 2010 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Enzo Biochem Annual EBITDA
(Millions of US $)
2022 $-12
2021 $3
2020 $-28
2019 $5
2018 $-9
2017 $0
2016 $51
2015 $3
2014 $-6
2013 $-14
2012 $-36
2011 $-8
2010 $-18
2009 $-20
Enzo Biochem Quarterly EBITDA
(Millions of US $)
2023-01-31 $-12
2022-10-31 $-9
2022-07-31 $-7
2022-04-30 $-2
2022-01-31 $-1
2021-10-31 $-1
2021-07-31 $-3
2021-04-30 $3
2021-01-31 $2
2020-10-31 $1
2020-07-31 $-4
2020-04-30 $-9
2020-01-31 $-7
2019-10-31 $-7
2019-07-31 $-5
2019-04-30 $23
2019-01-31 $-8
2018-10-31 $-5
2018-07-31 $-5
2018-04-30 $-2
2018-01-31 $-2
2017-10-31 $0
2017-07-31 $0
2017-04-30 $1
2017-01-31 $-0
2016-10-31 $-0
2016-07-31 $38
2016-04-30 $-2
2016-01-31 $8
2015-10-31 $6
2015-07-31 $10
2015-04-30 $-2
2015-01-31 $-3
2014-10-31 $-2
2014-07-31 $-2
2014-04-30 $0
2014-01-31 $-3
2013-10-31 $-2
2013-07-31 $-2
2013-04-30 $-4
2013-01-31 $-5
2012-10-31 $-3
2012-07-31 $-28
2012-04-30 $-2
2012-01-31 $-3
2011-10-31 $-3
2011-07-31 $-3
2011-04-30 $-1
2011-01-31 $-4
2010-10-31 $0
2010-07-31 $-5
2010-04-30 $-3
2010-01-31 $-9
2009-10-31 $-1
2009-07-31 $-4
2009-04-30 $-3
2009-01-31 $-7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00